Download - Bayer HealthCare

As an innovation- and growth-oriented company, Bayer HealthCare also invests in
setting up and maintaining collaborations with external partners. These partnerships
cover a broad variety of models ranging from r&D collaborations, licensing and co-
marketing agreements to regional alliances and acquisitions.
Strategic alliances with international partners from academia are an important pillar of the
company’s R&D strategy. Examples are the joint research center for innovative therapeutic
approaches at Tsinghua University (China) and the collaboration with the
German Cancer Research Center (Heidelberg). Other collaborations at earlier stage
include the multi-target drug discovery alliance with Evotec AG from Germany in the
area of endometriosis.
With the targeted anticancer drug Nexavar (sorafenib), the Pharmaceuticals Division
and Onyx Pharmaceuticals, Inc., USA, have gone all the way from drug discovery to
market. Another example in the area of Oncology is the successful co-development of
radium-223 dichloride with Algeta ASA from norway. Bayer HealthCare just recently
submitted this substance for marketing authorization in the EU and the United States
for the treatment of castration-resistant prostate cancer patients with bone metastases.
In collaboration with Regeneron Pharmaceuticals, Inc., Eylea (aflibercept) has
been successfully launched for the treatment of wet age-related macular degenera-
tion and central retinal vein occlusion. Another example of a fruitful partnership is the
co-development and co-promotion agreement with Janssen Pharmaceuticals for the
anticoagulant Xarelto (rivaroxaban). This collaboration has led to launches in multiple
locations worldwide.
Bayer HealthCare Animal Health recently acquired the U.S. animal health business of
Teva Pharmaceutical Industries. This transaction reinforces Bayer’s product offering in
the USA with anti-infectives for livestock and adds reproductive hormones to the
existing portfolio. The acquisition also strengthens the company’s companion animal
franchise with the addition of dermatological, pet wellness and nutraceutical products.
The Consumer Care Division continues to focus its business development efforts to
strengthen its position in the United States and to accelerate growth in emerging
markets including Brazil, China and Russia. In addition, the division will expand its
portfolio into adjacent business categories, as well as Rx to OTC switch opportunities.
BuSinESS DEvEloPMEnT
23